Cryoglobulinemia future or investigational therapies

	Cryoglobulinemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cryoglobulinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cryoglobulinemia future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cryoglobulinemia future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cryoglobulinemia future or investigational therapies
CDC on Cryoglobulinemia future or investigational therapies
Cryoglobulinemia future or investigational therapies in the news
Blogs on Cryoglobulinemia future or investigational therapies
Directions to Hospitals Treating Cryoglobulinemia
Risk calculators and risk factors for Cryoglobulinemia future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

In patients with acute, severe disease, plasmapheresis has been used in conjunction with high dose steroids and cytoxan.
- Uncontrolled studies demonstrated a reduction in creatinine in up to 87% of patients.